News tagged with bortezomib

Related topics: multiple myeloma

Bortezomib

Bortezomib (INN, originally codenamed PS-341; marketed as Velcade by Millennium Pharmaceuticals) is the first therapeutic proteasome inhibitor to be tested in humans. It is approved in the U.S. for treating relapsed multiple myeloma and mantle cell lymphoma. In multiple myeloma, complete clinical responses have been obtained in patients with otherwise refractory or rapidly advancing disease.

This text uses material from Wikipedia, licensed under CC BY-SA

Subscribe to rss feed